

\*\*\*\*Published June 2013\*\*\*\*

## MarketVIEW: Diabetes vaccines (CAT: VAMV043)

<b>Product Name</b>	:	<b>MarketVIEW: Diabetes vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation + 1 forecast model
<b>Therapeutic Area</b>	:	Novel vaccines
<b>Publication date</b>	:	June 2013
<b>Catalogue No</b>	:	VAMV043

## Background

Diabetes is a metabolic disorder where the pancreas produces little or no insulin (Type I) OR cells do not respond appropriately to insulin that is produced (Type II). It is estimated that the global prevalence of diabetes is estimated at over 371 million people, a number predicted to rise significantly by 2030. Diabetes, although manageable, can lead to a number of complications, many of which can be fatal. It is estimated that 4.6 million people aged between 20-79 died from diabetes in 2011.

Since Type 1 diabetes is an autoimmune disorder, there is a plausible role for a vaccine which may prevent or slow the damage being caused to the beta-cells in the pancreas. Consequently several different approaches have been explored involving immunomodulatory candidates. The most advanced clinical candidate has been Diamyd's, GAD (recombinant human glutamic acid decarboxylase protein) based therapy which is currently in Phase II clinical testing.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of diabetes vaccines across major Western<sup>1</sup> markets until 2030. The model contains value (\$ m) and volume (mio doses) predictions along with timeframe, pricing and penetration estimates for all adult/pediatric risk groups depending on stage of diabetes/risk profile. The product also includes an up-to-date review of disease epidemiology and competitor R&D pipeline activity.

---

<sup>1</sup> US, Canada, Australia, UK, France, Italy, Germany, Spain and Japan

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining diabetes epidemiology, disease indications and target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel vaccines has also been utilised.

### **PRODUCT CONTENTS:**

**Published June 2013 (CAT No: VAMV043)**

\*\*\*\*This product is composed of a model and summary presentation

Author's note  
Executive Summary  
Commercial model: key outputs  
Diabetes vaccine: available global market to 2030  
Diabetes vaccine: predicted global demand  
Diabetes vaccine: available market per country (USD \$) to 2030  
Diabetes vaccine: available US market to 2030 (base case)  
Diabetes vaccine: available EU market to 2030 (base case)  
Diabetes: disease background and epidemiology  
Diabetes: brief disease background  
Diabetes: clinical types  
Diabetes: global epidemiology  
Diabetes: US statistics  
Diabetes: UK statistics  
Diabetes: symptoms  
Diabetes: prediabetes  
Diabetes: diagnosis  
Diabetes: treatment overview  
Diabetes: treatment guidelines  
Diabetes: impact of the disease  
Diabetes: impact of the disease – complications  
Diabetes: impact of the disease – complications  
Diabetes: economic impact of the disease  
Diabetes: impact of the disease in the UK  
Diabetes vaccines: summary of development to date  
The role of a diabetes vaccine  
Diabetes vaccine approaches  
Diabetes vaccines in development  
The Diamyd approach  
Diabetes vaccine: modelling commercial potential  
Diabetes vaccine: target product profile  
Addressable vaccine populations  
Diabetes vaccine: model strategy  
Diabetes forecast: population flow  
Commercial model assumptions: overall

**Continued.....**

Commercial model assumptions by country  
Vaccine coverage assumptions by country (all cases)  
Bibliography  
Disclaimer  
About VacZine Analytics

**PAGES: ~55 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form**

**Contents – Vaccine demand models (MS Excel-based)**

Title sheet  
TOTAL CHARTS  
CHARTS – VALUE (high)  
CHARTS – VALUE (base)  
CHARTS – VALUE (low)  
CHARTS – VOLUME (high)  
CHARTS – VOLUME (base)  
CHARTS – VOLUME (low)  
Value summary (Total market)  
Volume summary (Total market)  
US (high)  
Canada (high)  
UK (high)  
Germany (high)  
France (high)  
Spain (high)  
Italy (high)  
Australia (high)  
Japan (high)  
US (base)  
Canada (base)  
UK (base)  
Germany (base)  
France (base)  
Spain (base)  
Italy (base)  
Australia (base)  
Japan (base)  
US (low)  
Canada (low)  
UK (low)  
Germany (low)  
France (low)  
Spain (low)  
Italy (low)  
Australia (low)  
Japan (low)  
Assumptions

**Worksheets = 65 interconnected**

## PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- o USD \$8995.00/ GBP £5620.00<sup>#</sup> (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

*# - indicative prevailing rate will be applied on date of transaction*

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY

1. National diabetes information clearinghouse (NDIC). Diabetes overview. Available at: <http://diabetes.niddk.nih.gov/dm/pubs/overview/index.aspx>. Accessed April 2013
2. IDF Diabetes Atlas Update 2012. Available at <http://www.idf.org/diabetesatlas/5e/Update2012>. Accessed April 2013
3. The Global Burden. Available at <http://www.idf.org/diabetesatlas/5e/the-global-burden>. Accessed April 2013
4. Diabetes at a glance – North America and Caribbean. Available at [http://www.idf.org/sites/default/files/IDF\\_NAC\\_5E\\_Update\\_FactSheet.pdf](http://www.idf.org/sites/default/files/IDF_NAC_5E_Update_FactSheet.pdf). Accessed April 2013
5. Diabetes at a glance 2012 – Europe. Available at [http://www.idf.org/sites/default/files/IDF\\_EUR\\_5E\\_Update\\_FactSheet1\\_0.pdf](http://www.idf.org/sites/default/files/IDF_EUR_5E_Update_FactSheet1_0.pdf). Accessed April 2013
6. IDF Diabetes Atlas. Available on [http://www.idf.org/sites/default/files/5E\\_IDFAtlasPoster\\_2012\\_EN.pdf](http://www.idf.org/sites/default/files/5E_IDFAtlasPoster_2012_EN.pdf). Accessed April 2013
7. Diabetes Data and Trends Diagnosed Diabetes. Available on <http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm>. Accessed April 2013
8. Diabetes Data and Trends, Incidence and Age at Diagnosis. Available on <http://www.cdc.gov/diabetes/statistics/incidence/fig1.htm>. Accessed April 2013
9. The Facts About Diabetes: A Leading Cause of Death in the UK. Available on <http://ndep.nih.gov/diabetes-facts/>. Accessed April 2013
10. Diabetes Data and Trends, Incidence and Age at Diagnosis. Available on <http://www.cdc.gov/diabetes/statistics/incidence/fig3.htm>. Accessed April 2013
11. Diabetes in the UK 2012. Available on <http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2012.pdf>. Accessed April 2013
12. Diabetes Symptoms. Available on <http://www.diabetes.co.uk/diabetes-symptoms.html>. Accessed April 2013
13. 13. Type II diabetes Symptoms. Available on: <http://www.diabetes.co.uk/type2-diabetes-symptoms.html>. Accessed: April 2013
14. Tabak et al. (2012) Prediabetes: a high-risk state for diabetes development. The Lancet, Volume 379, Issue 9833, Pages 2279 - 2290
15. Pre-Diabetes. Available on <http://www.diabetes.co.uk/pre-diabetes.html>. Accessed April 2013
16. American Diabetes Association, Diabetes Statistics. Available on <http://www.diabetes.org/diabetes-basics/diabetes-statistics/>. Accessed April 2013
17. Diabetes Diagnosis. Available on <http://www.diabetes.co.uk/Diabetes-diagnosis.html>. Accessed April 2013
18. Type 1 Diabetes. Available on <http://www.patient.co.uk/health/type-1-diabetes>. Accessed April 2013
19. Diabetes treatments. Available on <http://www.diabetes.org.uk/Guide-to-diabetes/Treatments/>. Accessed April 2013
20. Standards of medical care in diabetes – 2012. American Diabetes Association. Diabetes care, Volume 35, Supplement 1, January 2012
21. International diabetes Federation. Diabetes Atlas. Mortality. Available on <http://www.idf.org/diabetesatlas/5e/mortality>. Accessed April 2013
22. The Impact of Diabetes. Available on <http://www.doh.state.fl.us/family/dcp/whatis/impact.html>. Accessed April 2013
23. Diabetes Statistics. Available on <http://www.diabetes.org/diabetes-basics/diabetes-statistics/>. Accessed April 2013
24. Diabetes Research and Statistics. Available on <http://www.cdc.gov/diabetes/consumer/research.htm>. Accessed April 2013
25. Diabetes in the UK 2012. Available on <http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2012.pdf>. Accessed April 2013
26. Orban and Kis (2011) Prevention of Type 1 Diabetes Mellitus Using a Novel Vaccine. Ther Adv in Endo and Metab. 2011;2(1):9-16.
27. Diamyd trial listings. Available on <http://www.clinicaltrials.gov/ct2/results?term=diamyd&Search=Search>. Accessed May 2013
28. Selecta Biosciences. Vaccine pipeline. Available on <http://www.selectabio.com/pipeline/index.cfm>. Accessed May 2013
29. Diamyd Diabetes Clinical Trials. Available on <http://www.diamyd.com/docs/trialsDiabetes.aspx?section=trials>. Accessed May 2013
30. Type 1 diabetes: Cardiff researchers in vaccine trial. Available on <http://www.bbc.co.uk/news/uk-wales-21348607>. Accessed May 2013
31. Stop Diabetes, About the Trial. Available on <http://www.stopdiabetes.com.au/about/the-trial/>. Accessed May 2013
32. TB Vaccine Promising as New Way to Fight Type 1 Diabetes. Available on <http://healthyliving.msn.com/diseases/diabetes/tb-vaccine-promising-as-new-way-to-fight-type-1-diabetes>. Accessed May 2013

## TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

### VacZine Analytics

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and "the spiral logo" are UK Registered Trademarks, 2009